{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-21-013984","form_type":"8-K","ticker":"INCY","cik":"0000879169","company_name":"INCYTE CORP","filed_at":"2021-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:04:15.955383+00:00","generated_at":"2026-06-28T15:28:54.295003+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Incyte Q3 GAAP net income $181.7M vs loss, revenue $812.9M (+31%); multiple approvals","bullets":["Total product & royalty revenues $777.987M, +25% YoY; Jakafi $547.373M (+12%).","GAAP net income $181.739M ($0.82 diluted EPS) vs net loss $15.203M in Q3 2020.","Non-GAAP net income $261.824M ($1.18 diluted EPS) vs $50.059M.","FDA approved Opzelura for atopic dermatitis, Jakafi for chronic GVHD; Minjuvi OK'd in EU.","Reaffirmed FY2021 guidance: Jakafi net product rev $2,125-$2,170M; R&D $1,350-$1,390M GAAP."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-21-013984","json":"https://secwatch.observer/filing/0001558370-21-013984.json","markdown":"https://secwatch.observer/filing/0001558370-21-013984.md","text":"https://secwatch.observer/filing/0001558370-21-013984.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/879169/000155837021013984/0001558370-21-013984-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/879169/000155837021013984/incy-20211102x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T15:28:54.295003+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}